Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 12:38 AM
Ignite Modification Date:
2025-12-25 @ 12:38 AM
NCT ID:
NCT04093167
Brief Summary:
BR36 will evaluate the potential clinical benefit of tailoring immunotherapy treatment based on ctDNA molecular response in non-small cell lung cancer.
Detailed Description:
BR36 is an international multi-centre, open-label, biomarker-directed, phase II/III trial of ctDNA response adaptive immuno-chemotherapy in patients with immune checkpoint and chemotherapy naïve metastatic non-small cell lung cancer with ≥50% PD-L1 TPS expression. This trial will test if adding chemotherapy to pembrolizumab for patients with persistent ctDNA on Liquid Biopsy drawn at 6 weeks of treatment will result in better progression-free and overall survival compared to patients who remain on pembrolizumab therapy until clinical progression with subsequent change in standard therapy.
Study:
NCT04093167
Study Brief:
Protocol Section:
NCT04093167